Big data collection in pharmaceutical manufacturing and its use forproduct quality predictions

Past, Current, and Future: Application of Image Analysis in Small Molecule Pharmaceutical Development

The often-perceived limitations of image analysis have for many years impeded the widespread application of such systems as first line characterisation tools. Image analysis has, however, undergone a notable resurgence in the pharmaceutical industry fuelled by developments system capabilities and the desire of scientists to characterize the morphological nature of their particles more adequately. The importance of particle shape as well as size is now widely acknowledged. With the increasing use of modelling and simulations, and ongoing developments though the integration of machine learning and artificial intelligence, the utility of image analysis is increasing significantly driven by the richness of the data obtained. Such datasets provide means to circumvent the requirement to rely on less informative descriptors and enable the move towards the use of whole distributions. Combining the improved particle size and shape measurement and description with advances in modelling and simulations is enabling improved means to elucidate the link between particle and bulk powder properties. In addition to improved capabilities to describe input materials, approaches to characterize single components within multicomponent systems are providing scientists means to understand how their material may change during manufacture thus providing a means to link the behaviour of final dosage forms with the particle properties at the point of action. The aim is to provide an overview of image analysis and update readers with innovations and capabilities to other methods in the small molecule arena. We will also describe the use of AI for the improved analysis using image analysis.

Explainable deep recurrent neural networks for the batch analysis of a pharmaceutical tableting process in the spirit of Pharma 4.0

Due to the continuously increasing Cost of Goods Sold, the pharmaceutical industry has faced several challenges, and the Right First-Time principle with data-driven decision-making has become more pressing to sustain competitiveness. Thus, in this work, three different types of artificial neural network (ANN) models were developed, compared, and interpreted by analyzing an open-access dataset from a real pharmaceutical tableting production process. First, the multilayer perceptron (MLP) model was used to describe the total waste based on 20 raw material properties and 25 statistical descriptors of the time series data collected throughout the tableting (e.g., tableting speed and compression force). Then using 10 process time series data in addition to the raw material properties, the cumulative waste, during manufacturing was also predicted by long short-term memory (LSTM) and bidirectional LSTM (biLSTM) recurrent neural networks (RNN). The LSTM network was used to forecast the waste production profile to allow preventive actions. The results showed that RNNs were able to predict the waste trajectory, the best model resulting in 1096 and 2174 tablets training and testing root mean squared errors, respectively. For a better understanding of the process, and the models and to help the decision-support systems and control strategies, interpretation methods were implemented for all ANNs, which increased the process understanding by identifying the most influential material attributes and process parameters. The presented methodology is applicable to various critical quality attributes in several fields of pharmaceutics and therefore is a useful tool for realizing the Pharma 4.0 concept.

Big data collection in pharmaceutical manufacturing and its use forproduct quality predictions

Advances in data science and digitalization are transforming the world, and the pharmaceutical industry is no exception. Multiple sensor-equipped manufacturing processes and laboratory analysis are the main sources of primary data, which have been utilized for the presented dataset of 1005 actual production batches of selected medicine. This dataset includes incoming raw material quality results, compression process time series and final product quality results for the selected product. The data is highly valuable for it provides an insight into every 10 seconds of the process trajectory for 1005 actual production batches along with product quality collected over several years. It therefore offers an opportunity to develop advanced analysis models and procedures which would lead to the omission of current conventional and time consuming laboratory testing. Benefits for both the industry and patient are obvious: reducing product lead times and costs of manufacture.